Skip to main content
Premium Trial:

Request an Annual Quote

FLUOROtechnics, Sigma-Aldrich, Agilent Technologies, John Burton, Michael Rosinski, Jeff Warren, Gary Van Berkel, Hiroyuki Mitani, Robert Friel


New Products

Australia-based FLUOROtechnics, together with Sigma-Aldrich will be launching FluoroProfile, a protein quantification kit based on FLUOROtechnics' proprietary fluorophore epicocconone, on July 1. The kit can be used in a 96-well format, or on a membrane. It quantitates proteins by comparing sample fluorescence to the fluorescence of a standard. The kit can detect protein concentrations as low as 40 ng/ml.

FLUOROtechnics will manufacture the product, which will then be shipped to Sigma-Aldrich to be packaged, marketed and distributed. More information about FluoroProfile is available at

Agilent Technologies introduced last week its human protein Multiple Affinity Removal System which removes up to 99 percent of the six most common proteins from human blood serum. According to Agilent, the new system allows researchers to purify approximately twice the volume of serum per sample compared with other protein removal systems.

The new high-capacity affinity removal system is available in both HPLC column and spin cartridge formats. The products can be used for more than 200 runs, and are compatible with most standard LC instruments and benchtop centrifuges.


Movers & Shakers

John Burton has become chief accounting officer and controller of Power3 Medical Products, the proteomics company based in The Woodlands, Texas, said yesterday. He replaces Michael Rosinski, who resigned as chief financial officer "to pursue other business opportunities," according to the company. Burton comes to Power3 from Affiniscape, an Austin-based web site developer, where he was chief financial officer. He holds an MBA and a BBA from the University of Texas at Austin. Power3 said last week that it has been delisted from the over-the-counter bulletin board.

Jeff Warren has become the first non-executive director of Oxford Genome Sciences, the company said last week. In the past, he was the chief financial officer of Bristol and West Building Society and later the chief executive officer of Bristol and West.

Gary Van Berkel received the Biemann Medal of the American Society of Mass Spectrometry at the society's meeting last week for his contributions to the mass spec field. He is a group leader of the organic and biological mass spectrometry group at Oak Ridge National Laboratory's chemical sciences division. Van Berkel was honored for his work to better understand the electrochemical nature of the electrospray ion source. He holds a doctorate in analytical chemistry from Washington State University and a bachelor's degree in chemistry from Lawrence University in Wisconsin.

Hiroyuki Mitani has been appointed president and CEO of GE Healthcare Technologies, Japan. Mitani joined GE Japan in 1992 as director of business development. Prior to his current role, he served as general manager of marketing and sales for GE Transportation, Japan. In 1996, he served as general manager of marketing and sales for GE Energy, Japan.

Mitani received his MS in operations research from Stanford University in 1984 and an MS in mechanical engineering from the University of California, Berkeley, in 1983. He received his BS in mechanical engineering from the University of Tokyo in 1977.

Robert Friel has joined Millennium Pharmaceuticals' board of directors and will serve on the board's audit committee, the company said this week.

Friel currently serves as executive vice president and chief financial officer of PerkinElmer. Prior to joining PerkinElmer, Friel held a variety of senior finance positions at AlliedSignal, now Honeywell International. Friel also currently serves as a member of the board of directors of Fairchild Semiconductor Corporation.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.